Spaulding Clinical Research Announces New Strategic Partnership With Frontage Laboratories
Published: Sep 12, 2011
WEST BEND, Wis., Sept. 12, 2011/PRNewswire/ --Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer have entered into a strategic partnership agreement. This synergistic and cost-effective partnership establishes a global footprint by combining Frontage's presence in China and its expertise in drug formulation and Bioanalytical analysis, along with Spaulding Clinical's Cardiac Safety and fully-automated Clinical Pharmacology facility.
As part of the relationship, Spaulding Clinical will perform all intense electrocardiographic studies in its facility and provide ECG Core Lab services on behalf of Frontage. In return, Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding Clinical, as well as serve as one of the clinical sites for Spaulding Clinical clients in China.
"Throughout the due diligence process, we were thoroughly impressed with the innovative, quality-focused clinical conduct we witnessed at Spaulding," states Song Li, PhD, CEO and Chairman of Frontage Laboratories, Inc. "The collaboration with Spaulding Clinical will enable Frontage to better service our current and potential clients in a more comprehensive approach, especially in the areas of cardiac safety, thorough QT, and ECG Core Lab."
Randy Spaulding, CEO and Founder of Spaulding Clinical, states, "This collaboration represents another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development. Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China."
Jason Wu, MD, Sr. VP and General Manager of Frontage Clinical Services, states, "Spaulding's expertise in the Cardiac Safety aspects of clinical trials makes them the perfect partner to complement our clinical offering in both the US and China. We view the Spaulding iQ Electrocardiograph as a key innovation that enables the centralization of critical cardiac safety data in a cost-effective manner a need many of our clients have identified."
Frontage Laboratories, Inc. (www.frontagelab.com; www.frontagelab.com.cn) is a global full-service contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform. Frontage runs three Phase 1 Clinical units: a 72-bed Phase 1 Unit in Hackensack, NJ USA, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China and a-80 bed Phase 1 Unit in Changchun, Jilin Province China. Frontage has bioanalytical and CMC facilities in both the US (Bioanalytical lab in Malvern, PA; CMC facility in Exton, PA) and China (Bioanalytical lab in Shanghai; CMC facility in Beijing). The operations of biometrics and late phase services are based in both Exton, PA and Beijing, China. Frontage's preclinical animal facility is also located in Exton, PA. As a rapidly expanding CRO with a ten-year successful history of its high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.
Spaulding Clinical Research, LLC (www.spauldingclinical.com) provides Clinical Pharmacology, Cardiac Core Lab clinical research services and is a medical device manufacturer. Spaulding Clinical operates a 105-bed clinical pharmacology unit with 96-beds of Mortara telemetry in West Bend, Wisconsin. The facility is paperless with a phase I Electronic Data Capture system and bi-directional interfaces to safety lab, bedside devices and telemetry. As a Phase I-IV Core ECG Laboratory provider, Spaulding offers the complete suite of equipment provisioning and electrocardiograph over-reading services with state-of-the-art technologies, including the proprietary Spaulding iQ Electrocardiograph, and expertly trained cardiologists and project managers.
SOURCE Spaulding Clinical Research